Welcome to our dedicated page for Fibrobiologics SEC filings (Ticker: FBLG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company based in Houston that develops fibroblast-based therapies and fibroblast-derived materials for chronic diseases. These regulatory documents offer detailed information on the company’s capital structure, governance, financing arrangements, and stockholder proposals.
FibroBiologics’ filings include Forms 8-K describing material events such as securities purchase agreements, registered direct offerings, concurrent private placement warrants, use of sovereign-issued gold coins as consideration in one offering, and the payoff of convertible promissory notes issued under a Standby Equity Purchase Agreement. Other 8-K filings disclose Nasdaq notices related to minimum bid price and Market Value of Listed Securities requirements, along with the company’s potential options to address these listing standards.
The company’s proxy statements on Schedule 14A outline items submitted to stockholders, including a proposed reverse stock split within a specified ratio range, approvals for issuances of common stock underlying various warrant agreements under Nasdaq Listing Rule 5635(d), and an adjournment proposal. These documents also discuss voting rights, such as the Series C Preferred Stock with super voting rights and the irrevocable proxy in favor of the board of directors.
Through this page, users can review FibroBiologics’ annual and quarterly reports when available, current reports on Form 8-K, and proxy materials, with AI-powered tools that summarize key terms, highlight financing structures, and clarify complex provisions. Investors can also use the filings to understand warrant terms, reverse split authorizations, Nasdaq compliance disclosures, and other regulatory details that shape the risk and capital profile of FBLG.
FibroBiologics, Inc. approved a capital change by implementing a one-for-twenty reverse stock split of its common stock. The Certificate of Amendment became effective at 12:01 a.m. Eastern Time on March 30, 2026, converting every 20 issued and outstanding common shares into 1 share.
No fractional shares will be issued; any fractional share will be rounded up to the nearest whole share. The reverse split proportionately adjusts shares available under the equity incentive plan and existing options and warrants, but does not change the common stock’s par value, authorized share count, or the Nasdaq trading symbol FBLG.
FibroBiologics, Inc. completed a best-efforts public offering of 2,272,728 shares of common stock or equivalents and accompanying warrants, raising approximately $3 million in gross proceeds at a combined price of $1.32 per share and warrant. Net proceeds were about $2.5 million after fees, and are earmarked for working capital and general corporate purposes.
Investors also received warrants to purchase up to 2,272,728 additional shares at $1.32 per share, exercisable only after stockholder approval and expiring five years after that approval. If fully exercised for cash, these warrants could provide roughly $3 million in additional gross proceeds. Pre-funded warrants, issued at $1.31999 with a $0.00001 exercise price, are immediately exercisable and do not expire, subject to 9.99% beneficial ownership limits, while the other warrants and placement agent warrants carry a 4.99% ownership cap.
FibroBiologics is offering 1,028,788 shares of common stock, 1,243,940 pre-funded warrants and accompanying warrants to purchase up to 2,272,728 shares, at a combined public offering price of $1.32 per share plus warrant. Each public Warrant has an exercise price of $1.32 and is exercisable only after the effective date of the Warrant Stockholder Approval. Pre-Funded Warrants are exercisable for $0.00001 per share and are issued to limit single‑holder ownership above 4.99% (or electively 9.99%). The offering contemplates Placement Agent compensation including 159,091 Placement Agent Warrants and assumes delivery in a single closing. The prospectus gives effect to a 1-for-20 reverse stock split effective March 30, 2026, and states estimated net proceeds of approximately $2.5 million assuming full cash exercise of the Pre-Funded Warrants. The company remains listed on Nasdaq under FBLG and is taking these actions while seeking to regain compliance with Nasdaq bid-price requirements.
FibroBiologics, Inc. is registering up to 1,136,363 shares of common stock, up to 1,136,363 pre-funded warrants and related warrants in a best efforts public offering. Each share or pre-funded warrant is sold with a warrant, at an assumed combined price of $4.40. The company estimates net proceeds of about $4.3 million, intended for working capital and general corporate purposes. A 1-for-20 reverse stock split effective March 30, 2026 will reduce outstanding common shares from 70,256,883 to approximately 3,512,845, mainly to help regain Nasdaq bid-price compliance. The offering has no minimum size, may close with reduced proceeds and will cause immediate dilution for new investors.
FibroBiologics, Inc. filed Amendment No. 1 to its 2025 annual report to add the previously omitted Part III sections on directors, executive officers, compensation, security ownership, related‑party transactions and auditor fees. The company states the amendment does not change any prior financial results or other disclosures in the original 2025 report.
FibroBiologics, Inc. updated the compensation of its Chief Financial Officer. On March 4, 2026, the board’s Compensation Committee approved a new annual base salary of $400,000 for CFO Jason D. Davis, effective January 1, 2026. His target for annual non‑equity incentive compensation remains at 40% of base salary.
FibroBiologics, Inc. Chief Scientific Officer Hamid Khoja reported an open-market purchase of 30,000 shares of common stock at $0.3800 per share. Following this transaction, he directly owns 61,250 common shares.
FibroBiologics, Inc. chief executive officer Pete O'Heeron reported open-market purchases of 51,500 shares of common stock across three days. He bought 17,428 shares on March 2, 18,200 on March 3, and 15,872 on March 4, 2026, bringing his direct holdings to 5,958,147 shares.
FibroBiologics, Inc. Chief Financial Officer Jason Davis purchased 70,000 shares of the company’s common stock in an open-market transaction on March 2, 2026. The weighted average purchase price was $0.4139 per share, with individual trade prices ranging from $0.3968 to $0.4200. Following this transaction, Davis directly owns 70,000 common shares.
FibroBiologics, Inc. General Counsel Ruben A. Garcia bought 40,000 shares of common stock in an open-market purchase on February 27, 2026 at a weighted average price of $0.3264 per share. After this transaction, he directly owns 180,000 shares. The filing notes individual trade prices ranged from $0.3221 to $0.3268.